S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   435.81 (-2.42%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   435.81 (-2.42%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   435.81 (-2.42%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   435.81 (-2.42%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,376.17 (-2.99%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   467.50 (-3.29%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:CUECue Biopharma Stock Price, Forecast & News

$20.11
-0.96 (-4.56 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.06
Now: $20.11
$21.13
50-Day Range
$18.91
MA: $21.95
$25.92
52-Week Range
$6.95
Now: $20.11
$31.69
Volume200,306 shs
Average Volume297,568 shs
Market Capitalization$572.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUE
CUSIPN/A
Phone617-949-2680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.46 million
Book Value$2.37 per share

Profitability

Net Income$-36,700,000.00
Net Margins-959.08%

Miscellaneous

Employees46
Market Cap$572.13 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
$20.11
-0.96 (-4.56 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

How has Cue Biopharma's stock price been impacted by COVID-19 (Coronavirus)?

Cue Biopharma's stock was trading at $15.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CUE shares have increased by 28.0% and is now trading at $20.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cue Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cue Biopharma
.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Cue Biopharma
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) issued its quarterly earnings data on Tuesday, May, 19th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.15. Cue Biopharma had a negative return on equity of 103.99% and a negative net margin of 959.08%.
View Cue Biopharma's earnings history
.

What price target have analysts set for CUE?

4 analysts have issued 12-month price objectives for Cue Biopharma's shares. Their forecasts range from $30.00 to $33.00. On average, they expect Cue Biopharma's stock price to reach $31.25 in the next year. This suggests a possible upside of 55.4% from the stock's current price.
View analysts' price targets for Cue Biopharma
.

Has Cue Biopharma been receiving favorable news coverage?

Media coverage about CUE stock has been trending neutral this week, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cue Biopharma earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Cue Biopharma
.

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), Opko Health (OPK), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AT&T (T), AbbVie (ABBV), Dynavax Technologies (DVAX), Energy Transfer LP Unit (ET) and Iovance Biotherapeutics (IOVA).

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the following people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sigma Planning Corp (0.19%), Vident Investment Advisory LLC (0.19%), Vident Investment Advisory LLC (0.19%), Swiss National Bank (0.17%), Russell Investments Group Ltd. (0.12%) and Jennison Associates LLC (0.11%). Company insiders that own Cue Biopharma stock include Aaron GL Fletcher, Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar.
View institutional ownership trends for Cue Biopharma
.

Which institutional investors are selling Cue Biopharma stock?

CUE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sigma Planning Corp, UBS Group AG, and SG Americas Securities LLC. Company insiders that have sold Cue Biopharma company stock in the last year include Anish Suri, Christopher A Marlett, and Colin Sandercock.
View insider buying and selling activity for Cue Biopharma
.

Which institutional investors are buying Cue Biopharma stock?

CUE stock was bought by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, Vident Investment Advisory LLC, Swiss National Bank, Jennison Associates LLC, State Board of Administration of Florida Retirement System, Virtus ETF Advisers LLC, Leap Investments LP, and Rafferty Asset Management LLC. Company insiders that have bought Cue Biopharma stock in the last two years include Aaron GL Fletcher, Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri, and Kerri-Ann Millar.
View insider buying and selling activity for Cue Biopharma
.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $20.11.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $572.13 million and generates $3.46 million in revenue each year. The company earns $-36,700,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is www.cuebiopharma.com.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.